The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

PF-03654764 should reduce the symptoms of allergic rhinitis. In this study patients will be exposed to pollen and their symptoms observed.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Fexofenadine; Terfenadine

Criteria

Inclusion Criteria:

• Male or female subjects 18-60 years allergic to ragweed pollen.

• Subjects with appropriate symptom scores following exposure to ragweed in the environmental exposure unit.

Exclusion Criteria:

• Subjects with significant diseases other than allergic rhinitis that may interfere with the safety or efficacy of PF-03654764.

• Subjects with significant symptoms of allergic rhinitis within the 2 weeks prior to screening.